Stroup R M, Pinkus G S
Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115.
Hum Pathol. 1988 Aug;19(8):949-53. doi: 10.1016/s0046-8177(88)80011-x.
Immunoreactivity for S-100 protein, typically a marker for malignant melanoma and neural-derived tumors, was observed in neoplastic cells of 57 of 68 cases (84%) of formalin-fixed, paraffin-embedded primary and/or metastatic carcinoma of the breast of various histologic types. The extent of S-100 immunoreactivity varied, with only a minor proportion of positive tumor cells noted in some cases. An awareness of this staining profile for S-100 protein, particularly in metastatic poorly differentiated neoplasms with unknown primaries, is imperative for accurate immunohistochemical interpretation. Using a panel of reagents which includes antibodies to keratin proteins and epithelial membrane antigen, the epithelial nature of S-100-positive carcinomas may be readily defined. Tumor cells in all cases of primary and metastatic carcinoma of the breast evaluated in this study exhibited strong staining for both of these tissue markers. To preclude misinterpretation of tumor type due to anomalous staining patterns for a specific antibody, eg, S-100 protein, a panel of antibodies is recommended for assessment of metastatic poorly differentiated tumors.
在68例经福尔马林固定、石蜡包埋的不同组织学类型的原发性和/或转移性乳腺癌中，68例中的57例（84%）肿瘤细胞观察到S-100蛋白免疫反应性，S-100蛋白通常是恶性黑色素瘤和神经源性肿瘤的标志物。S-100免疫反应性的程度各不相同，在某些病例中仅发现一小部分阳性肿瘤细胞。认识到S-100蛋白的这种染色特征，尤其是在原发性不明的转移性低分化肿瘤中，对于准确的免疫组化解释至关重要。使用一组包括角蛋白抗体和上皮膜抗原抗体的试剂，S-100阳性癌的上皮性质可很容易地确定。在本研究中评估的所有原发性和转移性乳腺癌病例中，肿瘤细胞对这两种组织标志物均表现出强染色。为避免因特定抗体（如S-100蛋白）的异常染色模式而导致肿瘤类型的错误解读，建议使用一组抗体来评估转移性低分化肿瘤。
